Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

90Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin's Lymphoma.

Hernandez R, Walker KL, Grudzinski JJ, Aluicio-Sarduy E, Patel R, Zahm CD, Pinchuk AN, Massey CF, Bitton AN, Brown RJ, Sondel PM, Morris ZS, Engle JW, Capitini CM, Weichert JP.

Commun Biol. 2019 Feb 26;2:79. doi: 10.1038/s42003-019-0327-4. eCollection 2019.

2.

Preclinical Characterization of 86/90Y-NM600 in a variety of murine and human cancer tumor models.

Grudzinski JJ, Hernandez R, Marsh I, Patel R, Aluicio-Sarduy E, Engle J, Morris Z, Bednarz B, Weichert JP.

J Nucl Med. 2019 Apr 6. pii: jnumed.118.224808. doi: 10.2967/jnumed.118.224808. [Epub ahead of print]

PMID:
30954941
4.

Copper-64-labeled anti-bcl-2 PNA-peptide conjugates selectively localize to bcl-2-positive tumors in mouse models of B-cell lymphoma.

Jia F, Balaji BS, Gallazzi F, Lewis MR.

Nucl Med Biol. 2015 Nov;42(11):809-15. doi: 10.1016/j.nucmedbio.2015.06.002. Epub 2015 Jun 9.

PMID:
26239085
6.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
7.

111In-Ibritumomab tiuxetan.

The MICAD Research Team.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2005 Nov 22 [updated 2007 Sep 26].

8.

Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs).

DeNardo GL.

Semin Nucl Med. 2005 Jul;35(3):202-11.

PMID:
16098294
9.

High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma.

Ngeow JY, Quek RH, Ng DC, Hee SW, Tao M, Lim LC, Tan YH, Lim ST.

Ann Oncol. 2009 Sep;20(9):1543-7. doi: 10.1093/annonc/mdp030. Epub 2009 May 27.

PMID:
19474116
10.

Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.

Weiden PL, Breitz HB, Press O, Appelbaum JW, Bryan JK, Gaffigan S, Stone D, Axworthy D, Fisher D, Reno J.

Cancer Biother Radiopharm. 2000 Feb;15(1):15-29.

PMID:
10740649
11.

Dose intensified molecular targeted radiotherapy for cancer-lymphoma as a paradigm.

DeNardo G, DeNardo S.

Semin Nucl Med. 2010 Mar;40(2):136-44. doi: 10.1053/j.semnuclmed.2009.10.005. Review.

PMID:
20113681
12.

Targeted antisense radiotherapy and dose fractionation using a (177)Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate.

Liu D, Balkin ER, Jia F, Ruthengael VC, Smith CJ, Lewis MR.

Nucl Med Biol. 2015 Sep;42(9):704-10. doi: 10.1016/j.nucmedbio.2015.05.006. Epub 2015 May 29.

PMID:
26081917
13.

Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?

Reinhardt MJ, Herkel C, Altehoefer C, Finke J, Moser E.

Ann Oncol. 2005 Sep;16(9):1524-9. Epub 2005 Jun 9.

PMID:
15946979
14.

Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.

Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, Sparks RB, Stabin MG, Witzig T, White CA.

J Nucl Med. 2003 Mar;44(3):465-74.

15.

Treatment of T-cell non-Hodgkin's lymphoma.

Evens AM, Gartenhaus RB.

Curr Treat Options Oncol. 2004 Aug;5(4):289-303. Review.

PMID:
15233906
16.

Theranostic Approach for Metastatic Pigmented Melanoma Using ICF15002, a Multimodal Radiotracer for Both PET Imaging and Targeted Radionuclide Therapy.

Rbah-Vidal L, Vidal A, Billaud EM, Besse S, Ranchon-Cole I, Mishellany F, Perrot Y, Maigne L, Moins N, Guerquin-Kern JL, Degoul F, Chezal JM, Auzeloux P, Miot-Noirault E.

Neoplasia. 2017 Jan;19(1):17-27. doi: 10.1016/j.neo.2016.11.001. Epub 2016 Dec 14.

17.

FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.

Querellou S, Valette F, Bodet-Milin C, Oudoux A, Carlier T, Harousseau JL, Chatal JF, Couturier O.

Ann Hematol. 2006 Nov;85(11):759-67. Epub 2006 Jul 27.

PMID:
16871391
18.

Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?

Sharkey RM, Brenner A, Burton J, Hajjar G, Toder SP, Alavi A, Matthies A, Tsai DE, Schuster SJ, Stadtmauer EA, Czuczman MS, Lamonica D, Kraeber-Bodere F, Mahe B, Chatal JF, Rogatko A, Mardirrosian G, Goldenberg DM.

J Nucl Med. 2003 Dec;44(12):2000-18.

19.

ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells.

Talekar MK, Allen JE, Dicker DT, El-Deiry WS.

Cell Cycle. 2015 Aug 3;14(15):2422-8. doi: 10.1080/15384101.2015.1054086. Epub 2015 Jun 1.

20.

90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.

Griffiths GL, Govindan SV, Sharkey RM, Fisher DR, Goldenberg DM.

J Nucl Med. 2003 Jan;44(1):77-84.

Supplemental Content

Support Center